Shares of Kindred Biosciences Inc. — a darling of the Bay Area biotech IPO class of 2013 — fell more than 28 percent Thursday after the company revealed that its experimental osteoarthritis drug for dogs failed a key clinical trial. Dogs that received a placebo instead of the pain and inflammation drug CereKin had a better response rate than expected, the Burlingame company (NASDAQ: KIN) said. CereKin, known generically as diacerein, inhibits interleukin-1, a protein that becomes inflamed and…

Topics:  kindred biosciences inc   bay area   ipo   dogs   burlingame    nasdaq   cerekin   kin    failed   drug   company   

 

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News